Concord Drugs Limited

CONCORD6

INE858L01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:31:03 05/07/2024 pm IST			5-day change	1st Jan Change
38.63 ^INR	-2.35%		-0.67%	-35.31%

30/05	Concord Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
19/03	Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer	CI

Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2020

September 14, 2020 at 06:59 pm IST

Concord Drugs Limited announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced total revenue was INR 182.248 million compared to INR 133.422 million a year ago. Net income was INR 1.654 million compared to INR 1.343 million a year ago. Basic earnings per share from continuing operations was INR 0.189 compared to INR 0.15 a year ago.

Latest news about Concord Drugs Limited

Concord Drugs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	30/05	CI
Concord Drugs Limited Announces Appointment of Namratha Nagla as Company Secretary/Compliance Officer	19/03	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Concord Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/23/30	CI
Concord Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/23/30	CI
Concord Drugs Eyes INR 207 Million Rights Issue	14/23/14	MT
Concord Drugs Limited Announces Resignation of AnkurBisht, Company Secretary and Compliance Officer	08/23/08	CI
Concord Drugs Limited acquired 100% stake in Proton Remedies Private Limited for INR 14.2 million.	23/23/23	CI
Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023	14/23/14	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/23/14	CI
Concord Drugs Limited Announces Resignation of Rakshit Sethiya as Company Secretary and Compliance Officer	11/22/11	CI
Concord Drugs Limited announced that it has received INR 10.364063 million in funding	07/22/07	CI
Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer	04/22/04	CI
Concord Drugs Limited announced that it expects to receive INR 10.364063 million in funding	07/22/07	CI
Concord Drugs Limited agreed to acquire 100% stake in Proton Remedies Private Limited.	07/22/07	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	13/22/13	CI
Concord Drugs Limited Announces Director Changes	02/22/02	CI
Concord Drugs Limited Announces Resignation of Jyoti Goyal as Company Secretary and Compliance Officer	06/22/06	CI
Concord Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/22/14	CI
Concord Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	18/21/18	CI
Concord Drugs Limited Approves Appointment of S. Koni Reddy as Whole Time Director	08/21/08	CI
Concord Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	13/21/13	CI

Chart Concord Drugs Limited

Duration

Period

More charts

Company Profile

Concord Drugs Limited is an India-based pharmaceutical company. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup and suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellet system (MUPS). Its injectables include Amikacin Injection, Aceclofenac Injection, Artemether Injection, Adenosine Injection, and others. Iso Amyl 2-Cyano Acrylate is a tissue bio-adhesive. Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, and others.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CONCORD DRUGS LIMITED	-35.31%	4.74M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.69%	624B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.23%	240B
ROCHE HOLDING AG	+0.70%	219B
NOVARTIS AG	+14.68%	220B
AMGEN INC.	+7.42%	166B